Growth hormone-releasing hormone (GHRH) is a hypothalamic peptide hormone that stimulates synthesis and secretion of growth hormone from somatotroph cells of the anterior pituitary. It is produced primarily by neurons of the arcuate nucleus, released into the hypothalamo-hypophyseal portal circulation at the median eminence, and forms a major component of the hypothalamic regulation of the growth hormone-IGF-1 axis.
Growth hormone-releasing hormone (GHRH) is a hypothalamic peptide hormone that stimulates the synthesis and secretion of growth hormone (GH) from somatotroph cells of the anterior pituitary. It is one of the principal hypothalamic regulators of the growth hormone axis and functions in balance with the inhibitory hormone somatostatin.
GHRH is produced predominantly by neurosecretory neurons associated with the arcuate nucleus of the hypothalamus. Axons from these neurons project toward the median eminence, where GHRH is released into the primary capillary plexus of the hypothalamo-hypophyseal portal circulation. Portal blood then transports GHRH directly to the anterior pituitary.
At the anterior pituitary, GHRH binds receptors on somatotrophs, increasing growth hormone synthesis and secretion. Growth hormone subsequently acts directly on multiple tissues and stimulates production of insulin-like growth factor 1 (IGF-1), particularly by the liver. GHRH therefore occupies the hypothalamic level of the hypothalamic-pituitary-growth hormone-IGF-1 axis.
GHRH is a peptide hormone. The biologically active human hypothalamic forms include peptides derived from a larger precursor molecule.
Because GHRH is water soluble, it acts through receptors located on the plasma membrane of its target cells rather than crossing the membrane to bind intracellular receptors.
The principal hypothalamic neurons responsible for endocrine GHRH secretion are located primarily in and around the arcuate nucleus.
These neurons form part of the hypophysiotropic neuroendocrine system that controls anterior pituitary secretion.
The arcuate nucleus is located in the mediobasal hypothalamus near the third ventricle and median eminence. It contains several functionally distinct neuronal populations involved in endocrine and metabolic regulation.
GHRH-producing neurons project from this region toward the median eminence, allowing their secretory products to enter the pituitary portal circulation.
GHRH neurons are neurosecretory cells. They receive input from multiple neural and metabolic signaling systems and convert this information into episodic release of GHRH.
Their activity contributes importantly to the pulsatile pattern of growth hormone secretion.
GHRH is synthesized as part of a larger precursor protein. Following translation, the precursor undergoes intracellular processing to generate biologically active GHRH peptides.
The hormone is packaged within secretory vesicles and transported along neuronal processes toward terminals in the median eminence.
The median eminence is a specialized neurovascular region located at the base of the hypothalamus. It provides the major interface through which hypothalamic releasing and inhibiting hormones enter the circulation supplying the anterior pituitary.
GHRH-containing nerve terminals release their hormone close to fenestrated capillaries of the primary capillary plexus.
GHRH reaches the anterior pituitary through the hypothalamo-hypophyseal portal system. This specialized vascular arrangement connects capillaries of the median eminence with capillaries of the adenohypophysis.
The portal system allows hypothalamic GHRH to reach somatotrophs at effective concentrations without first being diluted throughout the systemic circulation.
| Step | Event |
|---|---|
| 1 | GHRH is synthesized by hypothalamic neurosecretory neurons |
| 2 | Axons project toward the median eminence |
| 3 | GHRH is released into the primary capillary plexus |
| 4 | Hypophyseal portal vessels carry GHRH toward the anterior pituitary |
| 5 | GHRH reaches the secondary capillary plexus |
| 6 | GHRH binds receptors on somatotroph cells |
| 7 | Growth hormone synthesis and secretion increase |
The principal endocrine target of GHRH is the somatotroph population of the anterior pituitary.
Somatotrophs synthesize and secrete growth hormone and represent one of the major endocrine cell populations of the adenohypophysis.
Somatotrophs are specialized endocrine cells responsible for growth hormone production. Their activity is regulated by stimulatory and inhibitory hypothalamic signals as well as peripheral feedback mechanisms.
GHRH provides a major stimulatory input, while somatostatin provides a major inhibitory input.
Growth hormone (GH), also called somatotropin, is a peptide hormone secreted by anterior pituitary somatotrophs.
GH influences growth, protein metabolism, lipid metabolism, carbohydrate metabolism, and tissue composition. Many of its growth-promoting effects are mediated through IGF-1.
GHRH acts through the GHRH receptor (GHRHR), a G protein-coupled receptor expressed prominently on anterior pituitary somatotrophs.
Activation of this receptor stimulates intracellular pathways that promote both GH release and GH synthesis.
The GHRH receptor is coupled primarily to stimulatory G proteins. Receptor activation stimulates adenylyl cyclase, increasing intracellular cyclic AMP.
Increased cAMP activates protein kinase-dependent pathways and modifies intracellular calcium signaling, promoting exocytosis of GH-containing secretory granules and increasing GH gene expression.
| Step | Event |
|---|---|
| 1 | GHRH binds GHRH receptors on somatotrophs |
| 2 | Stimulatory G protein signaling is activated |
| 3 | Adenylyl cyclase activity increases |
| 4 | Intracellular cAMP increases |
| 5 | Protein kinase and calcium-dependent signaling increase |
| 6 | Growth hormone secretion increases |
| 7 | Growth hormone synthesis is promoted |
GHRH does not merely trigger immediate release of stored GH. It also promotes transcription and synthesis of growth hormone within somatotrophs.
Long-term GHRH signaling therefore contributes to maintenance of the somatotroph population and its secretory capacity.
GHRH has trophic effects on pituitary somatotrophs. Normal GHRH signaling contributes to somatotroph development, proliferation, and maintenance.
Abnormalities of the GHRH receptor or chronic alterations in GHRH signaling can therefore affect both GH secretion and pituitary somatotroph biology.
Somatostatin, also called growth hormone-inhibiting hormone, is a hypothalamic peptide that inhibits GH secretion from somatotrophs.
Normal GH output reflects the dynamic interaction between stimulatory GHRH signaling and inhibitory somatostatin signaling.
| Feature | GHRH | Somatostatin |
|---|---|---|
| Primary effect on GH | Stimulation | Inhibition |
| Target | Anterior pituitary somatotroph | Anterior pituitary somatotroph |
| Transport | Hypophyseal portal circulation | Hypophyseal portal circulation |
| Effect on secretion | Promotes GH release | Suppresses GH release |
| Overall role | Stimulatory component of GH regulation | Inhibitory component of GH regulation |
Growth hormone is secreted in pulses rather than at a constant rate. These pulses reflect coordinated changes in hypothalamic GHRH and somatostatin activity together with other regulatory signals.
Periods of increased GHRH drive and reduced somatostatin restraint favor major GH secretory pulses.
The pulsatile pattern of GH secretion is an important characteristic of normal physiology. A single random measurement of circulating GH may therefore provide limited information about overall GH secretory function.
Integrated endocrine assessment often relies on downstream markers or dynamic testing rather than isolated GH concentrations.
Growth hormone stimulates production of insulin-like growth factor 1 (IGF-1) in multiple tissues, with the liver serving as a major source of circulating IGF-1.
IGF-1 mediates many of the growth-promoting effects associated with GH and also participates in feedback regulation of the axis.
| Level | Signal | Major Effect |
|---|---|---|
| Hypothalamus | GHRH | Stimulates anterior pituitary somatotrophs |
| Anterior pituitary | Growth hormone | Acts on tissues and stimulates IGF-1 production |
| Liver and peripheral tissues | IGF-1 | Mediates growth-related effects and provides feedback |
Insulin-like growth factor 1 is a peptide growth factor produced in response to GH stimulation. The liver contributes substantially to circulating IGF-1, while many peripheral tissues also produce IGF-1 locally.
IGF-1 promotes cellular growth and contributes importantly to skeletal and soft-tissue development.
Growth hormone participates in feedback regulation of its own axis. GH can influence hypothalamic regulation and reduce further GH secretion through direct and indirect mechanisms.
Feedback involves changes in both GHRH and somatostatin pathways.
IGF-1 provides important negative feedback within the growth hormone axis. Increased IGF-1 reduces GH secretion through actions at the pituitary and hypothalamic levels.
This feedback helps prevent uncontrolled activation of the GHRH-GH-IGF-1 system.
IGF-1 can act directly on anterior pituitary somatotrophs to reduce GH synthesis and secretion.
This represents one component of the peripheral negative feedback loop controlling GH output.
Peripheral signals associated with GH and IGF-1 influence hypothalamic regulation of both GHRH and somatostatin.
Negative feedback can reduce GHRH drive and enhance inhibitory somatostatin signaling, thereby decreasing GH secretion.
| Signal | Major Regulatory Effect |
|---|---|
| GHRH | Stimulates GH synthesis and secretion |
| Somatostatin | Inhibits GH secretion |
| GH | Provides feedback and stimulates IGF-1 production |
| IGF-1 | Provides negative feedback at pituitary and hypothalamic levels |
Ghrelin is another important stimulator of growth hormone secretion. It is produced prominently in the gastrointestinal tract and is also present within the central nervous system.
Ghrelin acts through the growth hormone secretagogue receptor and interacts functionally with hypothalamic and pituitary mechanisms controlling GH secretion.
| Feature | GHRH | Ghrelin |
|---|---|---|
| Major source | Hypothalamus | Predominantly stomach, with central production also present |
| Major endocrine effect | Stimulates GH | Stimulates GH |
| Receptor | GHRH receptor | Growth hormone secretagogue receptor |
| Role | Classical hypothalamic releasing hormone for GH | Metabolic and neuroendocrine modulator of GH secretion |
Growth hormone secretion is strongly associated with sleep. A major GH secretory pulse commonly occurs shortly after the onset of deep sleep.
Changes in hypothalamic GHRH and somatostatin activity contribute to this sleep-associated pattern.
The largest daily GH pulse in many individuals is associated with slow-wave sleep. This relationship is particularly prominent in younger individuals.
The connection between sleep architecture and GH secretion demonstrates the integration of hypothalamic neuroendocrine systems with behavioral and circadian physiology.
GH secretion demonstrates temporal organization involving sleep-associated and ultradian patterns. The timing of pulses reflects coordinated neural and endocrine regulation rather than a simple constant circadian output.
GHRH neurons participate in generating this episodic secretory pattern.
Physical exercise can stimulate GH secretion. The magnitude of the response depends on factors such as exercise intensity, duration, training status, age, nutritional state, and baseline endocrine physiology.
Hypothalamic regulation, including GHRH and somatostatin activity, contributes to this response.
Hypoglycemia is a physiological stimulus for GH secretion. GH participates in the broader counter-regulatory response to inadequate glucose availability.
Neural sensing of metabolic conditions can alter hypothalamic regulation of GHRH and somatostatin.
Nutritional status influences the GH axis. Fasting and changes in energy availability can alter GH secretion and the relationship between GH and IGF-1.
The endocrine response is complex because GH secretion, hepatic IGF-1 production, insulin availability, and nutrient status interact with one another.
Certain amino acids can influence GH secretion. Arginine, for example, can increase GH release partly by reducing somatostatin-mediated inhibition.
This illustrates how GH secretion can be altered through either increased stimulatory drive or reduced inhibitory tone.
Changes in circulating glucose influence GH secretion. Hypoglycemia can stimulate the axis, whereas acute hyperglycemia can suppress GH responses under some conditions.
These relationships are used in understanding physiological regulation and in selected dynamic endocrine tests.
The activity of the GH axis changes across the lifespan. GH secretion is high during periods of rapid growth and is particularly prominent around puberty.
Average GH secretion and pulse amplitude generally decline with advancing age.
Normal GHRH signaling is important for adequate pituitary GH secretion during childhood. GH and IGF-1 then contribute substantially to postnatal linear growth.
Disruption of hypothalamic GHRH signaling can therefore impair normal growth.
GH secretion increases during puberty. Sex steroids interact with the GH-IGF-1 axis and contribute to the pubertal increase in growth velocity.
Increased GH pulse amplitude and IGF-1 production support the adolescent growth spurt.
The growth-promoting effects initiated by GHRH ultimately influence the epiphyseal growth plates through GH and IGF-1 signaling.
IGF-1 promotes proliferation and differentiation of growth plate chondrocytes, contributing to longitudinal bone growth before epiphyseal closure.
Normal skeletal growth requires coordinated actions of GH, IGF-1, thyroid hormone, sex steroids, nutrition, and other physiological factors.
GHRH contributes indirectly by maintaining appropriate pituitary GH secretion.
The GH-IGF-1 system also influences growth and maintenance of soft tissues and organs. These effects reflect both direct actions of GH and growth-promoting effects mediated by IGF-1.
Although GHRH itself primarily targets the pituitary, the GH it stimulates has widespread metabolic effects. GH promotes protein synthesis, influences lipid mobilization, and modifies carbohydrate metabolism.
Thus, hypothalamic GHRH indirectly participates in systemic metabolic regulation through GH.
Growth hormone promotes amino acid uptake and protein synthesis in several tissues. These anabolic effects contribute to tissue growth and maintenance.
IGF-1 also participates in growth-related protein and cellular processes.
GH promotes mobilization and utilization of fatty acids. This contributes to shifts in fuel use during fasting and other metabolic states.
These actions are downstream consequences of hypothalamic-pituitary regulation of GH secretion.
Growth hormone has anti-insulin effects on aspects of carbohydrate metabolism and can reduce insulin sensitivity under conditions of sustained elevation.
The metabolic effects of GH differ from the growth-promoting effects mediated substantially through IGF-1.
Inadequate hypothalamic GHRH secretion can reduce stimulation of pituitary somatotrophs and lead to deficient GH secretion.
The consequences depend on age, severity, duration, and whether other hypothalamic-pituitary pathways are also affected.
Abnormalities affecting the GHRH receptor can impair somatotroph responsiveness to hypothalamic stimulation.
Severe loss of GHRH receptor function can result in profound GH deficiency and impaired postnatal growth.
When GH deficiency results from inadequate hypothalamic stimulation rather than intrinsic destruction of somatotrophs, pituitary cells may retain some capacity to respond to appropriate stimulation.
This distinction reflects the hierarchical organization of the hypothalamic-pituitary axis.
Damage or dysfunction of the anterior pituitary can directly impair GH production even when hypothalamic GHRH secretion is intact.
Other anterior pituitary hormones may also be affected depending on the extent of the lesion.
Persistent excessive GHRH stimulation can produce somatotroph hyperplasia and excessive GH secretion.
Although uncommon, excessive GHRH production can occur from hypothalamic or ectopic sources.
Some neuroendocrine tumors can produce ectopic GHRH. Excess circulating GHRH can chronically stimulate pituitary somatotrophs, resulting in increased GH secretion and somatotroph hyperplasia.
This can produce clinical features resembling those caused by a primary GH-secreting pituitary tumor.
Acromegaly results from chronic excessive GH activity after epiphyseal closure. Most cases arise from GH-secreting pituitary tumors, while ectopic GHRH production represents a much less common mechanism.
Understanding the GHRH-GH relationship helps distinguish hypothalamic or ectopic stimulation from autonomous pituitary GH secretion.
Excessive GH activity before closure of the epiphyseal growth plates can cause excessive linear growth. Rarely, chronic GHRH excess can contribute to this process by driving excessive pituitary GH secretion.
Administration of GHRH can stimulate pituitary GH release and has been used in specialized assessment of the growth hormone axis.
Responses depend on pituitary somatotroph reserve as well as the physiological and clinical context.
Because GH secretion is highly pulsatile, random GH measurements can be difficult to interpret. Dynamic endocrine tests may therefore be used to assess the capacity of the GH axis to respond to stimulation or suppression.
IGF-1 measurements are also useful because circulating IGF-1 is generally more stable than GH concentrations over short periods.
Synthetic compounds that reproduce or modify GHRH activity can stimulate endogenous GH secretion through the GHRH receptor.
Their effects depend on functional pituitary somatotrophs and an intact downstream GH signaling system.
GHRH stimulates the patient's own somatotrophs to release GH, whereas exogenous GH supplies the pituitary hormone directly.
This anatomical distinction means that GHRH-dependent approaches require sufficient functional somatotroph tissue.
Structural disruption of the pituitary stalk can interfere with delivery of GHRH from the hypothalamus to the anterior pituitary.
This may contribute to reduced GH secretion, particularly when multiple hypothalamic releasing pathways are disrupted.
Lesions affecting GHRH-producing neurons or their projections to the median eminence can impair hypothalamic stimulation of somatotrophs.
The endocrine consequences depend on lesion location and whether neighboring hypothalamic regulatory systems are also affected.
GHRH signaling contributes to the normal development and maintenance of somatotroph cells. The relationship between hypothalamic stimulation and pituitary cell populations therefore extends beyond acute hormone release.
Long-term disruption of GHRH signaling can alter somatotroph number and functional capacity.
| Feature | GHRH | Growth Hormone |
|---|---|---|
| Primary source | Hypothalamus | Anterior pituitary |
| Hormone class | Peptide | Peptide |
| Primary endocrine target | Somatotrophs | Multiple peripheral tissues |
| Primary transport route | Hypophyseal portal circulation | Systemic circulation |
| Major effect | Stimulates GH synthesis and secretion | Promotes metabolic effects and IGF-1 production |
| Feature | GHRH | IGF-1 |
|---|---|---|
| Major source | Hypothalamus | Liver and peripheral tissues |
| Position in axis | Upstream hypothalamic regulator | Downstream mediator and feedback signal |
| Major target in GH axis | Pituitary somatotroph | Growth-related tissues and feedback sites |
| Effect on GH secretion | Stimulates | Provides negative feedback |
| Feature | GHRH | CRH |
|---|---|---|
| Major hypothalamic source | Arcuate region | Paraventricular nucleus |
| Pituitary target | Somatotroph | Corticotroph |
| Pituitary hormone stimulated | Growth hormone | ACTH |
| Transport route | Hypophyseal portal circulation | Hypophyseal portal circulation |
| Major downstream mediator | IGF-1 | Cortisol |
| Feature | GHRH | Dopamine |
|---|---|---|
| Chemical class | Peptide hormone | Catecholamine |
| Primary pituitary target | Somatotroph | Lactotroph |
| Major effect | Stimulates GH | Inhibits prolactin |
| Portal transport | Yes | Yes |
GHRH demonstrates the vascular mode of communication between the hypothalamus and anterior pituitary. Hypothalamic neurons do not need to extend their axons directly to somatotroph cells.
Instead, GHRH is released into portal blood and distributed through the anterior pituitary capillary network, where it reaches its endocrine targets.
GHRH regulates an anterior pituitary hormone through the portal circulation. This differs from oxytocin and vasopressin, which are synthesized by hypothalamic neurons and transported down axons to the posterior pituitary.
The GHRH pathway therefore illustrates the characteristic neurovascular organization of the adenohypophysis.
| Factor | General Effect on GH |
|---|---|
| GHRH | Stimulates |
| Somatostatin | Inhibits |
| Ghrelin | Stimulates |
| IGF-1 | Provides negative feedback |
| Deep sleep | Associated with increased pulsatile secretion |
| Exercise | Can stimulate secretion |
| Hypoglycemia | Can stimulate secretion |
| Hypothalamic Hormone | Major Pituitary Target | Major Effect |
|---|---|---|
| GHRH | Somatotrophs | Stimulates GH |
| Somatostatin | Somatotrophs and thyrotrophs | Inhibits GH and TSH |
| CRH | Corticotrophs | Stimulates ACTH |
| TRH | Thyrotrophs | Stimulates TSH |
| GnRH | Gonadotrophs | Stimulates LH and FSH |
| Dopamine | Lactotrophs | Inhibits prolactin |
| Feature | Key Point |
|---|---|
| Full name | Growth hormone-releasing hormone |
| Alternative name | Somatocrinin |
| Hormone type | Peptide hormone |
| Major hypothalamic source | Arcuate nucleus and adjacent hypothalamic neurons |
| Release site | Median eminence |
| Transport route | Hypothalamo-hypophyseal portal circulation |
| Primary target | Anterior pituitary somatotrophs |
| Receptor | GHRH receptor |
| Major pituitary effect | Stimulates GH synthesis and secretion |
| Major opposing hypothalamic hormone | Somatostatin |
| Major downstream mediator | IGF-1 |
| Secretory pattern | Contributes to pulsatile GH secretion |
GHRH provides a clear example of the functional connection between the hypothalamus and anterior pituitary. Neurosecretory neurons in the hypothalamus synthesize GHRH and project toward the median eminence. Their terminals release GHRH into the primary capillary plexus rather than directly into the systemic circulation.
The hormone then travels through the hypothalamo-hypophyseal portal vessels to the anterior pituitary, where it reaches somatotroph cells through the secondary capillary plexus. Binding to GHRH receptors stimulates both immediate GH secretion and longer-term GH synthesis, linking hypothalamic neuronal activity to systemic endocrine function.
GHRH does not regulate GH in isolation. Somatostatin provides an opposing inhibitory influence, while ghrelin supplies an additional stimulatory signal. Coordinated changes in these pathways produce the characteristic pulsatile pattern of GH secretion, including prominent secretion associated with deep sleep.
Growth hormone released in response to GHRH acts on multiple tissues and stimulates production of IGF-1, particularly by the liver. IGF-1 mediates many growth-promoting actions of the axis and feeds back at pituitary and hypothalamic levels. The resulting regulatory network allows growth hormone output to respond to developmental stage, sleep, nutritional status, exercise, metabolic conditions, and peripheral growth signals.
Through its production in hypothalamic neurons, release at the median eminence, transport through the portal circulation, stimulation of pituitary somatotrophs, and integration with somatostatin and IGF-1 feedback, GHRH forms the principal hypothalamic stimulatory component of the growth hormone axis.